Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors

Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors

Abstract Background The T790M mutation is the major resistance mechanism to first- and second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet digital PCR (ddPCR) for detection of T790M in plasma circulating tumor DNA (ctDNA), and explore its impact on pro...

Full description

Bibliographic Details
Main Authors: Chun-Ta Huang, Chih-An Lin, Te-Jen Su, Ching-Yao Yang, Tzu-Hsiu Tsai, Chia-Lin Hsu, Wei-Yu Liao, Kuan-Yu Chen, Chao-Chi Ho, Chong-Jen Yu
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Cancer
Subjects:
Droplet digital polymerase chain reaction
EGFR mutation
Lung cancer
Osimertinib
Tyrosine kinase inhibitor
Online Access:https://doi.org/10.1186/s12885-023-10698-5

Internet

https://doi.org/10.1186/s12885-023-10698-5

Similar Items